A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
Open Access
- 14 November 2006
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 95 (12), 1637-1641
- https://doi.org/10.1038/sj.bjc.6603468
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Human Genomic Deletions Mediated by Recombination between Alu ElementsAmerican Journal of Human Genetics, 2006
- Capecitabine as third line therapy in patients with advanced colorectal cancerActa Oncologica, 2005
- Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced MalignanciesClinical Cancer Research, 2004
- Differential Alu Mobilization and Polymorphism Among the Human and Chimpanzee LineagesGenome Research, 2004
- Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal CarcinomaJournal of Clinical Oncology, 2004
- Phase II study of oral S‐1 for treatment of metastatic colorectal carcinomaCancer, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- DnaSP, DNA polymorphism analyses by the coalescent and other methodsBioinformatics, 2003
- Retrolyc1 subfamilies defined by different U3 LTR regulatory regions in the Lycopersicon genusMolecular Genetics and Genomics, 2001
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989